{"id":"W1881640566","doi":"10.1016/j.cgh.2014.01.029","title":"A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease","year":2014,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Placebo; Janus kinase inhibitor; Internal medicine; Adverse effect; Gastroenterology; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Clinical endpoint; Clinical trial; Phases of clinical research; Disease; Rheumatoid arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00143802,0.001194839,0.002558116,0.0004097651,0.000511923,0.001034243,0.000485034,0.001423804,0.003039381],"category_scores_gemma":[0.001117967,0.000634921,0.001739103,0.0003671563,0.0007986732,0.0009916306,0.0002807402,0.003138565,0.000545201],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008303153,"about_ca_system_score_gemma":0.001166926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009491104,"about_ca_topic_score_gemma":0.002592075,"domain_scores_codex":[0.9995844,0.0001772024,0.0000239333,0.0000760757,0.00003460452,0.0001038857],"domain_scores_gemma":[0.9993848,0.0001467528,0.00006587173,0.00004679958,0.00004275837,0.0003130626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8527607,0.02969027,0.007075562,0.0006535453,0.00153627,0.00050567,0.0002525921,0.001429929,0.02854568,0.0002552232,0.002806734,0.07448782],"study_design_scores_gemma":[0.8034266,0.1787114,0.0116515,0.00002908159,0.0006058476,0.0003846427,0.00006706864,0.0006493654,0.001475768,0.000159196,0.002810722,0.00002869063],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913264,0.003368072,0.0003734524,0.000925708,0.0002338238,0.0009235965,0.0008129661,0.00004746416,0.001988523],"genre_scores_gemma":[0.9899309,0.002409518,0.001299691,0.001302342,0.0002738823,0.001077959,0.002002459,0.00002195686,0.001681216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003039381,"threshold_uncertainty_score":0.01016778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01401290408214391,"score_gpt":0.3015733751171542,"score_spread":0.2875604710350103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}